Ireland’s Finance Minister Paschal Donohoe has admitted that US plans to introduce a global minimum corporation tax rate could have “a very meaningful effect” on corporate tax policy in Ireland. Ireland’s current corporate tax rate of 12.5% was introduced in 2003. The country has since become a hot spot for US-based multinationals including Google, Facebook, Microsoft, Pfizer and Johnson & Johnson.

The new measures would mean that if a US-based company paid tax at the lower Irish rate, the US could top up that company’s tax in its jurisdiction to bring it to the global minimum, therefore eradicating the tax advantage of establishing operations in Ireland. The Biden administration is currently planning to raise corporate taxes in the US and the new regulations will ensure it will not be undercut by other countries.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In fiscal plans published in April 2021, Donohoe predicted Ireland will lose €2bn ($2.4bn) in annual corporation tax collections by 2025. “Small countries such as Ireland need to be able to use tax policy as a legitimate lever to compensate for advantages of scale, resources and location enjoyed by larger countries,” he stated.

The proposed changes build on a project being led by the OECD focused on stimulating economic progress and world trade. Its base erosion and profit shifting project began in 2013 and aims to stop tax avoidance strategies that exploit gaps and mismatches in tax rules to avoid paying tax.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact